Planet Green Holdings Acquires Registered Lactoferrin Immunity Chewable Tablet, Accelerating Its Entry into Growing Immune-Health Market
NEW YORK, Nov. 17, 2026
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.

![]()
Planet Green Holdings Acquires Registered Lactoferrin Immunity Chewable Tablet, Accelerating Its Entry into Growing Immune-Health Market
PR Newswire
NEW YORK, Nov. 17, 2026
Subsidiary Taihe Bio Acquires Formulation, Production Technology and Chinese Health Food Registration Rights for Bovine Colostrum, Vitamin C and Lactoferrin Chewable Tablets; Asset-Light Contract Manufacturing Model Targets a Faster, Capital-Efficient Path to Market
NEW YORK, Nov. 17, 2026 /PRNewswire/ — Planet Green Holdings Corp. (NYSE American: PLAG) (“Planet Green” or the “Company”), a diversified holding company, today announced that its wholly-owned subsidiary, Hubei Taihe Biotechnology Co., Ltd. (“Taihe Bio”), has entered into a technology transfer agreement with Harbin Aikesailun Biotechnology Co., Ltd. (“Aikesailun Bio”) to acquire a registered immune-support health food product: Aikesailun-branded bovine colostrum, vitamin C and lactoferrin chewable tablets (the “Product”).
Under the agreement, Taihe Bio will acquire the Product’s proprietary formulation, production process, quality standards and related technical know-how, together with the associated health food registration certificate rights in China.
“This acquisition is a natural extension of our lactoferrin strategy,” said Mr. Bin Zhou, Chairman and Chief Executive Officer of Planet Green. “Rather than starting from scratch, we are securing an already-registered health food formulation that brings together three well-recognized immune-support ingredients: lactoferrin, bovine colostrum and vitamin C. This meaningfully strengthens our immunity product pipeline and moves us closer to delivering high-quality chewable tablet products to Chinese consumers. We believe it positions us well to capitalize on the continued growth of China’s lactoferrin market.”
Key Highlights
- Ready-made, registered product: The Product already holds a health food registration in China. Obtaining a new registration can be a lengthy and costly process; acquiring one allows the Company to bypass much of that time and expense.
- Development complete: Laboratory-scale and pilot-scale development are finished, positioning the Product for the next phase of commercialization.
- Asset-light model: Taihe Bio intends to use licensed contract manufacturers rather than build its own production facilities, designed to limit capital spending and speed time to market.
- Builds on existing strategy: The acquisition extends the Company’s previously announced lactoferrin sourcing, marketing and distribution initiative and its chewable immunity tablet program.
- Large, growing market: China held the largest country share of the global lactoferrin market in 2025, according to Grand View Research.
What Is Lactoferrin?
Lactoferrin is a naturally occurring protein found in milk, with its highest concentrations in colostrum, the nutrient-rich “first milk” produced in the days after birth. It is one of the body’s natural defense proteins and is widely used as an ingredient in premium infant formula, immune-support supplements and sports nutrition products. Because only small amounts can be extracted from milk, lactoferrin is a high-value specialty ingredient.
The Product combines lactoferrin with two other well-known immune-support ingredients: bovine colostrum (the first milk produced by cows after calving) and vitamin C, in an easy-to-take chewable tablet format.
Market Opportunity
According to Market Data Forecast, the global lactoferrin market is expected to grow from approximately US$278 million in 2026 to approximately US$519 million by 2034, representing a compound annual growth rate of approximately 8.1%. Grand View Research reports that China held the largest country share of that market in 2025.
Transaction and Next Steps
Under the agreement, Aikesailun Bio will hand over technical documentation and provide process transfer support. The parties will jointly apply to China’s State Administration for Market Regulation (SAMR) to transfer the registration certificate to Taihe Bio, which remains subject to regulatory approval. Following the transfer, Taihe Bio intends to engage qualified contract manufacturers holding the required production licenses to bring the Product to commercial production.
About Planet Green Holdings Corp.
Planet Green Holdings Corp. (“Planet Green”), headquartered in Flushing, New York, is a Nevada holding company operating through its subsidiaries in China and Canada. Planet Green operates a diversified business portfolio ranging from consumer products to online advertising. For more information, please visit the Company’s website at www.planetgreenholdings.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such statements are based on our management’s current expectations and beliefs, as well as a number of assumptions concerning future events. Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside of our control, all of which could cause actual results to differ materially from those discussed in the forward-looking statements. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in our reports filed with the U.S. Securities and Exchange Commission, which are available free of charge on the SEC’s website at www.sec.gov.
Investor Relations Contact
Planet Green Holdings Corp.
130-30 31st Avenue, Suite 512
Flushing, NY 11354
Tel: +1 347-370-2352
www.planetgreenholdings.com
View original content:https://www.prnewswire.com/news-releases/planet-green-holdings-acquires-registered-lactoferrin-immunity-chewable-tablet-accelerating-its-entry-into-growing-immune-health-market-302942037.html
SOURCE Planet Green Holdings Corp.


